Article Abstract

Editorial on “Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer”

Authors: Spencer Hart, Gopal Gupta


Renal cell carcinoma remains a common entity with approximately 65,340 new cases diagnosed in 2018. Given the insidious onset of disease, approximately 25–30% of patients will present with metastatic disease and require systemic therapy (1). Fortunately, the last two decades has seen the development of a number of targeted therapies including mammalian target of rapamycin (mTOR) inhibitors as well as tyrosine kinase inhibitors (TKIs) which are commonly used as first and second line therapies.

Article Options

Download Citation